{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T16:23:57Z","timestamp":1782923037650,"version":"3.54.5"},"reference-count":23,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T00:00:00Z","timestamp":1737763200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Melanoma is the fifth most common cancer in the United States. The advent of immunotherapy and molecular targeted therapy has improved progression-free and overall survival in many patients with advanced disease. However, the selection of therapeutic choices requires a nuanced approach, especially when considering molecularly targeted agents. This case report highlights a diagnostic and therapeutic challenge in managing a patient with a history of chronic lymphocytic leukemia (CLL) and recurrent melanoma. Molecular testing suggested discordant BRAF V600E testing and a simultaneous NRAS G12D mutation. After a careful literature review, repetition of his molecular testing, and analysis of the timelines and results of all his molecular testing, we concluded that the BRAF V600E mutation result was falsely positive. The patient was treated with two cycles of ipilimumab (1 mg\/kg) and nivolumab (3 mg\/kg) as per the NADINA trial and had a complete radiographic response. He then underwent resection demonstrating a pathologic partial response ranging from 20% to 95% tumor necrosis, dependent on the satellite examined. This case report underscores the importance of precise molecular diagnostics in guiding melanoma treatment and demonstrates the complexities of managing a patient with a coexisting malignancy.<\/jats:p>","DOI":"10.3390\/ijms26031029","type":"journal-article","created":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T03:54:27Z","timestamp":1737950067000},"page":"1029","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Recurrent Melanoma in a Patient with Chronic Lymphocytic Leukemia (CLL) Presenting with an Apparent Co-Existing NRAS and BRAF Mutation: A Diagnostic and Treatment Conundrum"],"prefix":"10.3390","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5802-2008","authenticated-orcid":false,"given":"Giuliana G.","family":"Berardi","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jabbar","family":"Muthanna","sequence":"additional","affiliation":[{"name":"Department of Pathology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y. Lynn","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pathology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5276-5898","authenticated-orcid":false,"given":"Anthony J.","family":"Olszanski","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,1,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"5549","DOI":"10.1158\/0008-5472.CAN-09-4254","article-title":"A mouse model of melanoma driven by oncogenic KRAS","volume":"70","author":"Milagre","year":"2010","journal-title":"Cancer Res."},{"key":"ref_3","unstructured":"Cancer Genome Atlas Network (2015). Genomic Classification of Cutaneous Melanoma. Cell, 161, 1681\u20131696."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.cell.2012.06.024","article-title":"A landscape of driver mutations in melanoma","volume":"150","author":"Hodis","year":"2012","journal-title":"Cell"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1111\/j.1755-148X.2011.00873.x","article-title":"Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma","volume":"24","author":"Devitt","year":"2011","journal-title":"Pigment Cell Melanoma Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1158\/1078-0432.CCR-10-2276","article-title":"Clinical correlates of NRAS and BRAF mutations in primary human melanoma [published correction appears in Clin. Cancer Res. 2011, 17, 1641]","volume":"17","author":"Ellerhorst","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_7","first-page":"6483","article-title":"NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression","volume":"9","author":"Omholt","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1097\/01.cmr.0000232300.22032.86","article-title":"NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: A study based on mutation screening by pyrosequencing","volume":"16","author":"Omholt","year":"2006","journal-title":"Melanoma Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1097\/CMR.0000000000000219","article-title":"Increased risk of melanoma in patients with chronic lymphocytic leukaemia: Systematic review and meta-analysis of cohort studies","volume":"26","author":"Olsen","year":"2016","journal-title":"Melanoma Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.leukres.2018.07.003","article-title":"Management of melanoma in patients with chronic lymphocytic leukemia","volume":"71","author":"Archibald","year":"2018","journal-title":"Leuk. Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.3109\/10428194.2012.742525","article-title":"BRAF mutations in chronic lymphocytic leukemia","volume":"54","author":"Jebaraj","year":"2013","journal-title":"Leuk. Lymphoma."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1182\/blood-2018-99-116293","article-title":"Mutations in the RAS pathway in pre-treatment chronic lymphocytic leukemia are associated with VH1-69: Linking B-cell receptor Stereotypy to downstream signaling events","volume":"132","author":"Jones","year":"2018","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1056\/NEJMoa2402604","article-title":"Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma","volume":"391","author":"Blank","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1093\/annonc\/mdy226","article-title":"Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma","volume":"29","author":"Tetzlaff","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1093\/annonc\/mdy218","article-title":"Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: A proposal for quantitative immune-related pathologic response criteria (irPRC)","volume":"29","author":"Cottrell","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_16","unstructured":"Cutaneous Melanoma: Laboratory Support of Diagnosis and Management (2024, November 16). Quest Diagnostics: Test Directory. (n.d.). Available online: https:\/\/testdirectory.questdiagnostics.com\/test\/test-guides\/CF_Melanoma\/cutaneous-melanoma-laboratory-support-of-diagnosis-and-management?p=td%29."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1200\/JCO.23.00205","article-title":"Targeting NRAS Mutations in Advanced Melanoma","volume":"41","author":"Phadke","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.annonc.2023.06.007","article-title":"Efficacy of immune checkpoint inhibitors for the treatment of advanced melanoma in patients with concomitant chronic lymphocytic leukemia","volume":"34","author":"Cass","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/bjh.18090","article-title":"Impact of chronic lymphocytic leukaemia on melanoma outcomes: A retrospective case-control study","volume":"197","author":"Jobson","year":"2022","journal-title":"Br. J. Haematol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1001\/jama.2014.3314","article-title":"Epidermal growth factor receptor tyrosine kinase inhibitors vs conventional chemotherapy in non-small cell lung cancer harboring wild-type epidermal growth factor receptor: A meta-analysis","volume":"311","author":"Lee","year":"2014","journal-title":"JAMA"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S1470-2045(12)70269-3","article-title":"Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: A phase 1 dose-escalation trial","volume":"13","author":"Falchook","year":"2012","journal-title":"Lancet Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ejca.2022.02.008","article-title":"MEK inhibitors for pre-treated, NRAS-mutated metastatic melanoma: A multi-centre, retrospective study","volume":"166","author":"Salzmann","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/nrclinonc.2013.83","article-title":"Paradoxical oncogenesis\u2014The long-term effects of BRAF inhibition in melanoma","volume":"10","author":"Gibney","year":"2013","journal-title":"Nat. Rev. Clin. Oncol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/3\/1029\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T10:36:04Z","timestamp":1759919764000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/3\/1029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,25]]},"references-count":23,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["ijms26031029"],"URL":"https:\/\/doi.org\/10.3390\/ijms26031029","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,25]]}}}